Compare NXT & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXT | PODD |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 17.0B |
| IPO Year | 2023 | 2007 |
| Metric | NXT | PODD |
|---|---|---|
| Price | $113.61 | $238.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 20 |
| Target Price | $105.50 | ★ $358.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.0M |
| Earning Date | 04-27-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.97 | N/A |
| EPS | 2.86 | ★ 3.48 |
| Revenue | ★ $2,959,197,000.00 | $2,708,100,000.00 |
| Revenue This Year | $19.73 | $24.33 |
| Revenue Next Year | $11.74 | $19.33 |
| P/E Ratio | ★ $35.43 | $68.27 |
| Revenue Growth | 18.38 | ★ 30.73 |
| 52 Week Low | $36.06 | $233.29 |
| 52 Week High | $131.59 | $354.88 |
| Indicator | NXT | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 37.50 |
| Support Level | $111.03 | N/A |
| Resistance Level | $130.17 | $299.75 |
| Average True Range (ATR) | 5.56 | 7.33 |
| MACD | -1.02 | 0.36 |
| Stochastic Oscillator | 62.44 | 16.06 |
Nextpower (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextpower's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextpower has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.